艾昆纬(IQVIA) IQV

Mr. Ari Bousbib, Education: Master of Business Administration, Columbia University; Master of Science in Mathematics and Mechanical Engineering, Ecole Superieure des Travaux Publics, Paris. Recent Experience: IQVIA Holdings Inc. (2016-present) - Chairman and Chief Executive Officer. IMS Health Holdings, Inc. (2010-2016) - Chairman and Chief Executive Officer. Prior Experience: President of UTC's commercial companies (Otis Elevator Company, Carrier Corporation, UTC Fire & Security and UTC Power Inc.), among other roles, at United Technologies Corporation; Partner at Booz Allen Hamilton. U.S. public company directorships: The Home Depot, Inc. (Finance Committee and Audit Committee). Former U.S. public company directorships: IMS Health (predecessor to IQVIA); Best Buy, Inc. Other positions: Member, Harvard Medical School Health Care Policy Advisory Council; Former member, President's Commission on White House Fellowships.

Mr. Grenfell has served as President, Commercial Solutions since December 2025. Mr. Grenfell previously served as President, Europe, Middle East, Africa and South Asia Regional Business Unit from January 2020 to December 2025. In addition, Mr. Grenfell led IQVIA's Global Public Health initiatives during this time. From May 2015 to December 2019, Mr. Grenfell served as President, North Europe, Middle East, Africa and South Asia. Since joining IMS Health, IQVIA's predecessor company, in 1996, Mr. Grenfell has held sales, client services and business management roles of increasing responsibility in EMEA. Mr. Grenfell holds a Bachelor of Arts degree with honors in Business Economics from Anglia Ruskin University and a Master of Science in Economics and Competition Policy from Bayes Business School, City St. George's, University of London.

Mr. Sherbet has served as our Executive Vice President, General Counsel and Secretary since March 2018. Prior to joining the Company, he served as General Counsel and Secretary at Patheon N.V. from November 2014 until November 2017. Prior to joining Patheon, he was General Counsel and Corporate Secretary at InVentiv Health from April 2011 until October 2014. He also previously served as Vice President, Deputy General Counsel and Corporate Secretary at Foster Wheeler AG and before that, as Vice President, Corporate and Securities Law and Secretary with Avaya, Inc. Mr. Sherbet earned his law degree from New York University School of Law and received his bachelor's degree in commerce/accounting from University of Virginia.

Dr. John M. Leonard, M.D., Lead Independent Director. Education: Doctorate in Medicine, Johns Hopkins University; Bachelor of Arts in Biochemistry, University of Wisconsin-Madison. Recent Experience: Intellia Therapeutics, Inc. (2014-present)- President and Chief Executive Officer (2018-Present), Executive Vice President, Research and Development (2017-2018), Chief Medical Officer (2014-2017). Prior Experience: Chief Scientific Officer and Senior Vice President of Research and Development at AbbVie Inc; Senior Vice President of Global Pharmaceutical Research and Development, among other roles, at Abbott Laboratories. U.S. public company directorships: Intellia Therapeutics, Inc.

Mr. James A. Fasano, Independent Director. Education: Master of Business Administration, University of Chicago Graduate School of Business; Bachelor of Engineering, Royal Military College of Canada. Recent Experience: University of Chicago Booth School of Business (2023-present) - Adjunct Professor. Prior Experience: Managing Director at CPP Investment Board; Member of Investment Banking group at Merrill Lynch & Co.; Member of Mergers and Acquisitions group at RBC Capital Markets; Commissioned Officer in the Canadian Armed Forces. Former U.S. public company directorships: IMS Health (predecessor to IQVIA). Other positions: Member, Board of Directors, Asurion (Compensation Committee Chair, Nominating and Governance Committee); LHP Hospital Group; AWAS Aviation Capital.

Carol J. Burt, Independent Director. Education: Bachelor of Arts in Business Administration, the University of Houston. Recent Experience: Burt-Hilliard Investments (2008-present) - Principal; Consonance Capital Partners (2013-present): Senior Advisor, Member, Operating Council. Prior Experience: SVP Corporate Finance and Development, among other roles, at Wellpoint, Inc. (f/k/a Anthem, Inc. and now Elevance Health, Inc.); Founder, Managing Director and Head of the Health Care Banking Group, among other roles, at Chase Securities (now J.P. Morgan). Former U.S. public company directorships: Envision Healthcare Corporation; WellCare Health Plans, Inc; Vanguard Health Systems; Transitional Hospitals Corporation. Other positions: Member, Board of Directors: WellDyneRx, LLC; Member: Women Corporate Directors; International Women's Forum. U.S. public company directorships: Resmed Inc. (Audit Committee, Compliance, Privacy and Quality Committee, and Nominating and Governance Committee (Chair)).

Ms. Colleen A. Goggins, Independent Director. Education: Masters in Management, Kellogg School of Management; Bachelor of Science in Food Chemistry, University of Wisconsin-Madison. Recent Experience: SIG Combibloc Group (2015-2023) - Member, Advisory Board (2015-2017), Member, Board of Directors (2018-2023); Bayer AG (2017-present) - Member, Supervisory Board. Prior Experience: Member of Executive Committee and Worldwide Chair of Consumer Group, among other roles at Johnson & Johnson. U.S. public company directorships: The Toronto-Dominion Bank (Risk Committee). Former U.S. public company directorships: Bausch Health Companies Inc. (f/k/a Valeant Pharmaceuticals International). Other positions: Member: Citymeals-on-Wheels New York City; University of Wisconsin Foundation; Member, Board of Trustees: Institute of International Education.

Mr. John G. Danhakl, Independent Director. Education: Master of Business Administration, Harvard Business School; Bachelor of Arts in Economics, University of California at Berkeley. Recent Experience: Leonard Green & Partners, L.P. (1995-present) - Managing Partner. Prior Experience: Managing Director of Donaldson, Lufkin & Jenrette Securities Corporation; Vice President at Drexel Burnham Lambert, Inc. U.S. public company directorships: Life Time Group Holdings, Inc. (Compensation Committee, Nominating and Corporate Governance Committee); Mister Car Wash, Inc. Former U.S. public company directorships: IMS Health (predecessor to IQVIA). Other positions: Member, Board of Directors: CNG (Charter Next Generation); Convergint Technologies LLC; Lakeshore Learning; Parts Town; Pye-Barker Fire Safety, LLC; WellSky Corporation.

Ms. Sheila A. Stamps, Independent Director. Education: Master of Business Administration, University of Chicago; Bachelor of Science in Management, Duke University; ESG Certificate and Designation from Competent Boards Professional Development and Advisory Services. Prior Experience: EVP, Corporate Strategy and Investor Relations at DBI, LLC; Commissioner, New York State Insurance Fund; Director, Pensions and Cash Management at New York State Common Retirement Fund; Managing Director at Bank of America; Managing Director at Bank One Corporation (now JPMorgan Chase). U.S. public company directorships: MFA Financial, Inc. (Compensation Committee and Nominating and Corporate Governance Committee). Former U.S. public company directorships: Pitney Bowes Inc; Atlas Air Worldwide Holdings, Inc; CIT Group Inc; Forest Road Acquisition Corp. Other positions: Member, Board of Trustees: Bankinter Innovation Foundation.

Ms. Leslie Wims Morris, Independent Director. Education: Master of Business Administration, Harvard Business School; Bachelor of Arts in English, Yale University. Recent Experience: JPMorgan Chase (2022-present) - Chief Executive Officer, Chase Auto. Prior Experience: President, Private Label Captive Finance, Chase Auto; Managing Director and Head of Corporate Development, Consumer & Community Banking at JPMorgan Chase; VP, Executive Partnerships at American Express; SVP, Strategy and Business Development at Broadridge Financial Solutions; SVP at Jefferies & Company. Other positions: Vice Chair, Board of Trustees: Dance Theatre of Harlem.

Dr. William G. Kaelin, Jr,M.D. Education: Doctorate in Medicine, Duke University School of Medicine; Bachelor of Arts in Mathematics, Duke University; Associate Bachelor in Chemistry, Duke University. Recent Experience: Harvard Medical School - Sidney Farber Professor of Medicine (2018-present); Professor of Medicine (2002-2018). Dana-Farber Cancer Institute - Professor (2002-present). Howard Hughes Medical Institute - Investigator (2002-present); Assistant Investigator (1998-2002). U.S. public company directorships: Eli Lilly and Company (Directors and Corporate Governance Committee, Science and Technology Committee (Chair)). Other highlights: Recipient of numerous noteworthy scientific awards, including: Nobel Prize in Physiology or Medicine; Albert Lasker Basic Medical Research Award; Canada Gairdner International Award; Wiley Prize in Biomedical Sciences from the Rockefeller University; Paul Marks Prize for Cancer Research from the Memorial Sloan Kettering Cancer Center.

Mr. Todd B. Sisitsky, Independent Director. Education: Master of Business Administration, Stanford Graduate School of Business; Bachelor of Arts, Dartmouth College. Recent Experience: TPG, Inc. (2003-present) - President & Co-Managing Partner of TPG Capital (2015-present), President of TPG, Inc. (2021-present). Prior Experience: Executive at Forstmann Little & Company; Executive at Oak Hill Capital Partners; Member, Board of Directors: Surgical Care Affiliates, Inc. (Nominating and Corporate Governance Committee). U.S. public company directorships: Allogene Therapeutics, Inc. (Nominating and Corporate Governance Committee); TPG, Inc. (Executive Committee). Former U.S. public company directorships: Convey Health Solutions Holdings, Inc; Endo International plc; IASIS Healthcare LLC; IMS Health (predecessor to IQVIA). Other positions: Chair, Board of Advisors, Dartmouth Medical School; Member, Board of Directors: Ellodi Pharmaceuticals; Immucor Inc. (Compensation Committee); Monogram Health, Inc.; Exatech, Inc.; Convey Holding Parent, Inc.; Confluent Medical Technologies.

Mr. Haas has served as Executive Vice President, AI and Technology Solutions since December 2025. Mr. Haas previously served as Senior Vice President, Digital Products & Solutions from January 2024 to December 2025. Mr. Haas has over 20 years of experience in the healthcare and pharmaceutical industry. He joined IQVIA in 2013 and had responsibility for the Technology Solutions business across Europe, Middle East, Africa and South Asia. Before joining IQVIA, Mr. Haas was an associate principal at McKinsey and Company leading the pharma multi-channel marketing group. Prior to McKinsey, he held various roles at Bayer Pharmaceuticals, including country manager Denmark and sales & marketing head, Poland. Mr. Haas holds a master's degree in international business from the University of Bamberg.

Mr. Patel has served as President, MedTech and Consumer Health since December 2025. Prior to that, he served as President, Commercial Solutions from July 2022 to December 2025. Mr. Patel also previously served as Senior Vice President, Global Market Insights and MedTech from September 2018 to July 2022. Prior to that, Mr. Patel held roles of increasing responsibility within IQVIA's Global Market Insights business. Before joining IQVIA in 2005, Mr. Patel began his career in the healthcare industry at Schwarz Pharma in 2003, where he was responsible for sales to healthcare professionals.

Mr. Fedock has served as our Senior Vice President, Financial Planning and Analysis since April 2021. From July 2019 to April 2021, Mr. Fedock served as the CFO for the Company's Research & Development Solutions Business Unit and from May 2016 to July 2019, he served as CFO of IQVIA Laboratories (formally known as Q2 Solutions, a joint venture between the Company and Quest Diagnostics Incorporated and a leading clinical trial laboratory services organization). Prior to joining IQVIA Laboratories, Mr. Fedock spent 13 years with ICON plc where he held various roles of increasing responsibility in both financial and operational leadership positions. Mr. Fedock has a bachelor's degree in biological sciences from Drexel University and a Master of Business Administration from the University of Baltimore.

IQVIA Holdings Inc. announced today the appointment of Keriann Cherofsky as Senior Vice President, Corporate Controller and principal accounting officer of the Company, effective August 1, 2022. Ms. Cherofsky, age 38, brings 16 years of relevant experience to her new role. From March 2019 to August 2022, she served as Assistant Controller of the Company. From November 2015 to March 2019, she led SEC reporting as Executive Director of JPMorgan Chase & Co. Prior to this, beginning in September 2006, she held various positions of increasing responsibility in PricewaterhouseCoopers LLP's banking and capital markets assurance practice, most recently as Senior Manager.

Mr. Berkshire has served as our Executive Vice President, Global Infrastructure and Operations since December 2025. Mr. Berkshire previously served as Executive Vice President, Global Technology and Operations from January 2024 to December 2025. Prior to that, he was Senior Vice President, Business Operations, where he focused on operational excellence, productivity improvements and cost management. Previously, Mr. Berkshire was Vice President, Organizational Effectiveness at IMS Health, IQVIA's predecessor company. Mr. Berkshire has a Bachelor of Arts degree in economics from Indiana University.

Mr. Staub resumed the role of President, Research & Development Solutions on September 25, 2023. From April 2022 through September 2023, Mr. Staub was senior advisor to the Chairman and CEO of IQVIA. Mr. Staub had served as President, Research & Development Solutions from November 2016 to March 2022. Previously, Mr. Staub served as President of Novella Clinical, a Quintiles company, since 2013. Prior to Novella's 2013 acquisition by Quintiles, Mr. Staub served as both president and CEO of Novella Clinical since 2008. Before joining Novella Clinical in 2004, Mr. Staub was senior vice president of global business development for one of the world's largest clinical research organizations. Mr. Staub's career in the pharmaceutical industry began at Zeneca Pharmaceuticals in 1989 where he had progressive responsibilities as a medical and hospital sales representative, cardiovascular portfolio analyst and marketing manager. Mr. Staub has a Bachelor of Arts degree in Economics from the University of North Carolina at Chapel Hill.